Free Trial
OTCMKTS:CVSI

CV Sciences (CVSI) Stock Price, News & Analysis

CV Sciences logo
$0.03 0.00 (-4.94%)
As of 05/23/2025 01:23 PM Eastern

About CV Sciences Stock (OTCMKTS:CVSI)

Key Stats

Today's Range
$0.02
$0.03
50-Day Range
$0.03
$0.03
52-Week Range
$0.02
$0.10
Volume
712,048 shs
Average Volume
228,973 shs
Market Capitalization
$4.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Stock News Headlines

Q1 2025 CV Sciences Inc Earnings Call
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Q4 2024 CV Sciences Inc Earnings Call
See More Headlines

CVSI Stock Analysis - Frequently Asked Questions

CV Sciences' stock was trading at $0.0338 on January 1st, 2025. Since then, CVSI shares have decreased by 26.0% and is now trading at $0.0250.
View the best growth stocks for 2025 here
.

CV Sciences, Inc. (OTCMKTS:CVSI) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The business earned $5.13 million during the quarter, compared to the consensus estimate of $5.12 million. CV Sciences had a negative net margin of 16.24% and a negative trailing twelve-month return on equity of 101.85%.

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KushCo (KSHB), NVIDIA (NVDA) and Organigram (OGI).

Company Calendar

Last Earnings
8/12/2021
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.10 million
Pretax Margin
-16.26%

Debt

Sales & Book Value

Annual Sales
$16 million
Cash Flow
$0.01 per share
Price / Cash Flow
1.75
Book Value
$0.02 per share
Price / Book
1.25

Miscellaneous

Free Float
182,392,000
Market Cap
$4.62 million
Optionable
Not Optionable
Beta
0.70

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (OTCMKTS:CVSI) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners